Psoriatic Arthritis

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA.

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

This post-hoc analysis demonstrated an association between work productivity and stringent disease control criteria for those with psoriatic arthritis.

These data, presented at ACR 2024, demonstrate that response was maintained at 2 years among those with psoriatic arthritis who responded to bimekizumab at Week 16.

Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.

Secukinumab is best for severe skin involvement, while adalimumab improves synovitis in PsA. Both are effective, but larger studies are needed for long-term outcomes.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.

Gender, age, and disease duration significantly affected symptom variations.

Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

Types of occupation did not significantly affect response to treatment.

This interview at the Fall 2024 Maui Derm conference features Melodie Young, with a discussion about updates in psoriasis and psoriatic arthritis therapy for children.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Wells discussed the PrismRA blood test, which may benefit planning treatment regimens for patients with rheumatic disease.